Premium
Immunohistochemical Assessment of the Growth Fraction in Cervical Cancers Using the Monoclonal Antibody Ki‐67; Relationship to the Clinical Stage, Histologic Type and DNA Content
Author(s) -
Masuda Tomoyuki,
Yabushita Hiromitsu,
Sawaguchi Keizo,
Noguchi Masayoshi,
Nakanishi Masami
Publication year - 1992
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1992.tb00303.x
Subject(s) - immunohistochemistry , cervical cancer , monoclonal antibody , stage (stratigraphy) , pathology , cancer , ki 67 , medicine , monoclonal , antibody , biology , immunology , paleontology
To assess the growth potential of cervical cancer, cell populations in proliferating cycle (%PC) were examined by an immunohistochemical technique using the monoclonal antibody Ki‐67. The %PC was 31.63+16.61% in 36 cervical cancers and was significantly higher when compared to the 7.8±3.81% found in 24 samples of normal ectocervical tissues. In cervical cancer tissues, the %PC increased in accordance with progression of the clinical stage of the disease, however, the %PC was not different among the various histologic types of invasive cervical cancers. The DNA index also increased in accordance with progression of the clinical stage of cervical cancer, however, there was no correlation between the %PC and the DNA index. These results suggest that the value of %PC obtained using the monoclonal antibody Ki‐67 can be used as a parameter for evaluating the growth activity of cervical cancer and for predicting biological heterogeneity in a tumor.